Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Counterfeits: FDA Says Serono Serostim Tracking Is Effective Solution

Executive Summary

Serono's tracking system for Serostim has attracted FDA's attention as an effective anti-counterfeiting technology
Advertisement

Related Content

Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
Track-And-Trace: With Deadline A Year Away, Some Lessons From Early Adopters
Manufacturers’ Anticounterfeiting Plans Sought In House Cmte. Investigation
FDA Anti-Counterfeiting Public Meeting To Display Current Technology
Public Sector Reimportation Programs Violate FD&C Act, FDA Tells Calif.
FDA Counterfeiting Task Force To Look At Tighter Wholesaler Licensing
Rx Imports: House Cmte. Tells FDA To Consider “Counterfeit-Proof” Packages
Wholesalers Seek Rx Coalition To Create Product Tracking System
Serono Serostim Distribution Program To Help Reconcile Medicaid Rebates
Serono Serostim Distribution Program To Help Reconcile Medicaid Rebates
Advertisement
UsernamePublicRestriction

Register

PS042403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel